Leiomyoma Clinical Trial
Official title:
Prospective Blinded Study Looking at PO/IV Analgesia Alone Versus PO/IV Analgesia With Superior Hypogastric Nerve Block for Uterine Artery Embolization Pain Management
Uterine fibroid embolization (UFE) is now an accepted treatment of uterine fibroids. However the procedure is often very painful and, in many centres, patients are admitted overnight with patient controlled analgesic (PCA) pumps for pain control and discharged the next day with heavy pain medications. The goal of this study is to evaluate the effectiveness of a superior hypogastric nerve block (SHGNB) in controlling the pain post-UFE.
This is a double blinded study in which the patients and the primary operators of the UFE as
well as the post-procedural caregivers are blinded to whether the patients have received a
sham procedure (injection of xylocaine in the skin in the peri-umbilical region) or the
superior hypogastric nerve block.
The superior hypogastric nerve block (SHGNB) consists of advancing a 21g Chiba needle via an
anterior approach up to the superior hypogastric nerve plexus and injecting 20cc of 0.75%
Ropivacaine which is a long lasting local anesthetic agent. The nerve plexus is positioned
below the aortic bifurcation along the anterior surface of the vertebral body. By
fluoroscopy, the location can be identified by having a catheter crossing the aortic
bifurcation. That way, we are able to target, under fluoroscopy, the anterior surface of the
vertebral body just below the catheter.
Our UFE starts with a right common femoral artery (CFA) access. The catheter is crossed to
the left side and the left uterine artery embolized with polyvinyl alcohol (PVA) 500-700
particles. The operator will then leave the room. Another operator will come and perform
either the hypogastric nerve block or the sham procedure (injection of xylocaine in the
periumbilical subcutaneous tissues). If the hypogastric nerve block is done, the needle is
advanced into position via an anterior periumbilical approach under fluoroscopic guidance.
Once the bony surface is contacted, 3 cc of xylocaine is injected to numb the area and then
3-6 cc of contrast is injected to ensure that it drapes the anterior vertebral body surface.
If it spreads along both sides of the vertebral body and there is no vascular intravasation
of contrast, the 20 cc of Ropivacaine is injected. If it only drapes one side, 10 cc is
injected and the needle repositioned to the other side, the position verified with contrast,
and the left over 10 cc of Ropivacaine injected.
After the block or sham procedure is done, the primary operator enters the room again and the
UFE completed with embolization of the right uterine artery.
The patient is transferred to the recovery room and monitored. Pain medication including
fentanyl and midazolam are offered at routine interval or on patient request. Pain scales are
measured routinely and the patient is discharge home with a pain survey with visual analog
pain scales to be performed routinely for 10 days.
The patient is followed up in 4-6 months with a follow-up magnetic resonance imaging (MRI)
and consultation to look at the results of the procedure.
Comparison of the pain scale reports and use of pain medication will be evaluated between
both groups to determine if there is a statistically significant difference.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04172272 -
The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures
|
N/A | |
Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
Completed |
NCT00156195 -
Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids
|
Phase 3 | |
Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
Completed |
NCT00160381 -
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
|
Phase 3 | |
Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
Completed |
NCT00044876 -
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
|
Phase 2 | |
Completed |
NCT02889848 -
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
|
Phase 1 | |
Recruiting |
NCT04145518 -
Mechanistic Characterization of Uterine Pain
|
Phase 4 | |
Completed |
NCT01816815 -
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
|
Phase 1 | |
Completed |
NCT00891657 -
Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy
|
N/A | |
Completed |
NCT00156156 -
Study of Asoprisnil in the Treatment of Uterine Fibroids.
|
Phase 3 | |
Recruiting |
NCT05538689 -
Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)
|
Phase 4 | |
Active, not recruiting |
NCT03323905 -
Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas
|
N/A | |
Terminated |
NCT03342859 -
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
|
Phase 1 | |
Recruiting |
NCT06135870 -
Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
|
||
Completed |
NCT02777203 -
Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy
|
N/A | |
Completed |
NCT02189083 -
Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids
|
Phase 3 | |
Completed |
NCT01123603 -
Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata
|
N/A |